What is King Pharmaceuticals's revenue?

King Pharmaceuticals (KG) generated $43.4M in revenue over the trailing twelve months, up 1160.2% year over year.

Is King Pharmaceuticals profitable?

King Pharmaceuticals reported $57.0M in net income over the trailing twelve months, a 131.4% net margin.

What is King Pharmaceuticals's earnings per share?

King Pharmaceuticals's diluted EPS over the trailing twelve months is $13.30.

Where does King Pharmaceuticals's income statement data come from?

Every line is extracted from King Pharmaceuticals's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.

King Pharmaceuticals KG Income Statement

Income Statement Balance Sheet Cash Flow Ratios Segments

Quarterly Annual TTM

YoY QoQ

Simplified Detailed

	TTM Q1 '26	TTM Q4 '25	TTM Q3 '25	TTM Q2 '25	TTM Q1 '25
Net investment income	——	——	——	——	——
Net premiums earned	$15.83M—	$12.67M—	$9.26M—	$2.42M—	$0—
Total revenue	$43.4M+1,160%	$34.05M+785%	$25.06M—	$8.37M—	$3.44M—
General and administrative	$39.66M+757%	$29.06M+469%	$18.13M—	$8.53M—	$4.63M—
Income from equity method investments	$23K—	$24K—	-$24K—	$0—	——
Gain (loss) on disposal of assets	$8.3M—	$6.96M—	$6.55M—	$1.06M—	$0—
Income before income taxes	——	——	——	——	——
Income tax expense	——	——	$132K—	$125K—	$122K—
Net income	——	——	——	——	——
Income from continuing operations	——	——	——	——	——
Income from discontinued operations	-$5,000.55—	-$5,000.49—	$1,000.00—	$1,000.00—	$0.00—
Diluted earnings per share	——	——	——	——	——
Basic earnings per share	——	——	——	——	——
Weighted-average shares, diluted	25.9M+135%	20.9M—	17.9M—	12.9M—	11M—
Weighted-average shares, basic	25.9M+135%	20.9M—	17.9M—	12.9M—	11M—
Increase in unearned premiums	$6.97M—	$6.46M—	$4.27M—	$1.33M—	$0—
Gross premiums written (Note 5)	$8.75M—	$6.09M—	$4.86M—	$1.1M—	$0—
Net premiums written	$8.86M—	$6.21M—	$4.99M—	$1.1M—	$0—
Policyholder Benefits And Claims Incurred Net	$11.25M—	$8.99M—	$4.45M—	-$5.96M—	$0—
Continuing operations (in dollars per share)	——	——	——	——	——
Continuing operations (in dollars per share)	——	——	——	——	——
Discontinued operations (in dollars per share)	-$0.49—	-$0.43—	-$0.23—	-$0.11—	$0—
Benefits, Losses and Expenses, Net	——	——	——	——	——
Net cash provided by operating activities from the Prepaid Business	-$3.63M—	-$2.95M—	-$1.93M—	-$1.19M—	——
Deferred Policy Acquisition Costs, Amortization Expense	$4.6M—	$3.13M—	$2.11M—	$394K—	$0—
Depreciation, Amortization and Accretion, Net	$272K—	$281K—	$60K—	$2.89M—	——
Investment management and advisory fees	$8.39M+157%	$6.08M+67.2%	$4.15M—	$3.23M—	$3.26M—
Foreign exchange and other gains, net	——	——	——	——	——
Income (Loss) from Continuing Operations, Net of Tax, Attributable to Parent	——	——	——	——	——
Increase in accrued expenses and other liabilities	-$12.93M-809%	-$18.74M-1,093%	$31.42M—	$7.67M—	-$1.42M—
Loss and loss adjustment expense reserves	-$71.02M—	-$54.28M—	-$47.25M—	-$25.09M—	——
Increase (Decrease) in Other Operating Assets	——	——	——	——	-$828.75K—
Interest and amortization expenses	$13.76M—	$9.87M—	$5.65M—	$1.52M—	——
Net interest and investment income (loss)	$10.89M+5,849%	$8.34M+3,817%	$5.1M—	$1.66M—	$183K—
Cash Provided by (Used in) Financing Activity, Including Discontinued Operation	——	——	——	-$40M—	——
Cash Provided by (Used in) Investing Activity, Including Discontinued Operation	$199.94M—	$146.95M—	$104.41M—	$88.33M—	——
Cash Provided by (Used in) Operating Activity, Including Discontinued Operation	-$110.4M—	-$96.14M—	-$30.65M—	-$21.44M—	——
Net Cash Provided By Used In Operating Activities Continuing Operations	-$106.77M—	-$93.19M—	-$28.72M—	-$20.25M—	——
Payment for (Proceeds from) Other Investing Activity	$28K—	$21K—	$18K—	$1K—	——
Payments to Acquire Equity Method Investments	$1.55M—	$1.08M—	$604K—	$490K—	——
Premiums Written, Net	$8.86M—	$6.21M—	$4.99M—	$1.1M—	$0—
Other investments, net of payments	$4.19M—	$2.95M—	$1.07M—	$141K—	——
Sale of investments	$100.91M—	$62.79M—	$15.19M—	$7.31M—	——

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Ask your AI about King Pharmaceuticals.

Connect your AI assistant and get a quick read on the numbers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is King Pharmaceuticals's revenue?: King Pharmaceuticals (KG) generated $43.4M in revenue over the trailing twelve months, up 1160.2% year over year.
Is King Pharmaceuticals profitable?: King Pharmaceuticals reported $57.0M in net income over the trailing twelve months, a 131.4% net margin.
What is King Pharmaceuticals's earnings per share?: King Pharmaceuticals's diluted EPS over the trailing twelve months is $13.30.
Where does King Pharmaceuticals's income statement data come from?: Every line is extracted from King Pharmaceuticals's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.